12:28 PM EDT, 06/28/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday results from a phase 3 study of nipocalimab in generalized myasthenia gravis were "positive."

Patients treated with nipocalimab plus standard of care achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the Myasthenia Gravis- Activities of Daily Living score from baseline over 24 weeks, the company said.

It said the trial also achieved key secondary endpoints including improvement in strength and function of different muscle groups.

Nipocalimab's safety and tolerability were consistent with previous studies, the company added.

The study is part of Johnson & Johnson's ( JNJ ) presentation at the European Academy of Neurology Congress.

Price: 146.61, Change: +0.81, Percent Change: +0.56